AKTX Stock Summary and Trading Ideas (Akari Therapeutics PLC - American Depositary Shares | NASDAQ:AKTX)

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.

As of July 10, 2026, AKTX stock price climbed to $13.88 with 61,494 million shares trading.

AKTX has a beta of 2.98, meaning it tends to be more sensitive to market movements. AKTX has a correlation of 0.03 to the broad based SPY ETF.

AKTX has a market cap of $24.30 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, AKTX traded as high as $220.00 and as low as $3.02.

AKTX has underperformed the market in the last year with a return of -69.7%, while SPY returned +21.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AKTX shares. However, AKTX has outperformed the market in the last 3 month and 2 week periods, returning +262.4% and +29.4%, while SPY returned +11.4% and +3.6%, respectively. This indicates AKTX has been having a stronger performance recently.

AKTX support price is $11.61 and resistance is $14.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.